Peter A. Riedell

Jul 7, 2024 | nature.com | Mazyar Shadman |Madiha Iqbal |Nausheen Ahmed |Peter A. Riedell |Natalie Grover |Nilanjan Ghosh | +8 more

AbstractIn patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a CR. A retrospective observational study comparing auto-HCT (2015–2021) vs. CAR-T (2018–2021) using the Center for International Blood & Marrow Transplant Research registry.

Sep 19, 2023 | onclive.com | Peter A. Riedell

Peter Riedell, MD, assistant professor of Medicine, Section of Hematology and Oncology, The University of Chicago Department of medicine, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma (FL).